In situ Measurement of Biaxial Modulus of Si Anode for Li-ion Batteries

We report in situ measurement of biaxial moduli of a Si thin-film electrode as a function of its lithium concentration. During lithiation, biaxial compressive stress is induced in the Si film and it undergoes plastic flow. At any state-of-charge (SOC), a relatively small delithiation-relithiation sequence unloads and reloads the film elastically. From the stress and strain changes during a delithiation-relithiation cycle, the biaxial modulus of the film is calculated. Stress change is obtained by measuring the change in substrate curvature using a Multi-beam Optical Sensor; the elastic strain change is obtained from the change in SOC. By repeating these measurements at several different values of SOC, the biaxial modulus was seen to decrease from ca. 70 GPa for Li0.32Si to ca. 35 GPa for Li3.0Si. Such a significant reduction in elastic modulus has important implications for modeling stress evolution and mechanical degradation in Si-based anodes.Comment: 8 pages, 3 figure

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice. OBJECTIVE We test the ability of GSK1521498 to reduce alcohol consumption and compare its intrinsic efficacy to that of naltrexone by comparing the two drugs at doses matched for equivalent receptor occupancy. METHODS Thirty-six C57BL/6J mice were tested in a DID procedure. In 2-day cycles, animals experienced one baseline, injection-free session, and one test session when they received two injections, one of test drug and one placebo. All animals received GSK1521498 (0, 0.1, 1 and 3 mg/kg, i.p., 30 min pre-treatment) and naltrexone (0, 0.1, 1 and 3 mg/kg, s.c. 10 min pre-treatment) in a cross-over design. Receptor occupancies following the same doses were determined ex vivo in separate groups by autoradiography, using [3H]DAMGO. Binding in the region of interest was measured integrally by computer-assisted microdensitometry and corrected for non-specific binding. RESULTS Both GSK1521498 and naltrexone dose-dependently decreased ethanol consumption. When drug doses were matched for 70-75 % receptor occupancy, GSK1521498 3 mg/kg, i.p., caused a 2.5-fold greater reduction in alcohol consumption than naltrexone 0.1 mg/kg, s.c. Both GSK1521498 and naltrexone significantly reduced sucrose consumption at a dose of 1 mg/kg but not 0.1 mg/kg. In a test of conditioned taste aversion, GSK1521498 (3 mg/kg) reduced sucrose consumption 24 h following exposure to a conditioning injection. CONCLUSIONS Both opioid receptor antagonists reduced alcohol consumption but GK1521498 has higher intrinsic efficacy than naltrexone

Normalization of Sequential Top-Down Tree-to-Word Transducers

International audienceWe study normalization of deterministic sequential top-down tree-to-word transducers (STWs), that capture the class of deterministic top-down nested-word to word transducers. We identify the subclass of earliest STWs (eSTWs) that yield normal forms when minimized. The main result of this paper is an effective normalization procedure for STWs. It consists of two stages: we first convert a given STW to an equivalent eSTW, and then, we minimize the eSTW. Keywords: formal language theory, tree automata, transformations, XML databases, XSLTExtended Version: A long version is available here.</p

Neurochemical enhancement of conscious error awareness

How the brain monitors ongoing behavior for performance errors is a central question of cognitive neuroscience. Diminished awareness of performance errors limits the extent to which humans engage in corrective behavior and has been linked to loss of insight in a number of psychiatric syndromes (e.g., attention deficit hyperactivity disorder, drug addiction). These conditions share alterations in monoamine signaling that may influence the neural mechanisms underlying error processing, but our understanding of the neurochemical drivers of these processes is limited.Weconducted a randomized, double-blind, placebo-controlled, cross-over design of the influence of methylphenidate, atomoxetine, and citalopram on error awareness in 27 healthy participants. The error awareness task, a go/no-go response inhibition paradigm, was administered to assess the influence of monoaminergic agents on performance errors during fMRI data acquisition. A single dose of methylphenidate, but not atomoxetine or citalopram, significantly improved the ability of healthy volunteers to consciously detect performance errors. Furthermore, this behavioral effect was associated with a strengthening of activation differences in the dorsal anterior cingulate cortex and inferior parietal lobe during the methylphenidate condition for errors made with versus without awareness. Our results have implications for the understanding of the neurochemical underpinnings of performance monitoring and for the pharmacological treatment of a range of disparate clinical conditions that are marked by poor awareness of errors

GraphM : an efficient storage system for high throughput of concurrent graph processing

With the rapidly growing demand of graph processing in the real world, a large number of iterative graph processing jobs run concurrently on the same underlying graph. However, the storage engines of existing graph processing frameworks are mainly designed for running an individual job. Our studies show that they are inefficient when running concurrent jobs due to the redundant data storage and access overhead. To cope with this issue, we develop an efficient storage system, called GraphM. It can be integrated into the existing graph processing systems to efficiently support concurrent iterative graph processing jobs for higher throughput by fully exploiting the similarities of the data accesses between these concurrent jobs. GraphM regularizes the traversing order of the graph partitions for concurrent graph processing jobs by streaming the partitions into the main memory and the Last-Level Cache (LLC) in a common order, and then processes the related jobs concurrently in a novel fine-grained synchronization. In this way, the concurrent jobs share the same graph structure data in the LLC/memory and also the data accesses to the graph, so as to amortize the storage consumption and the data access overhead. To demonstrate the efficiency of GraphM, we plug it into state-of-the-art graph processing systems, including GridGraph, GraphChi, PowerGraph, and Chaos. Experiments results show that GraphM improves the throughput by 1.73~13 times

Covalent chemical modification of self- assembled fluorocarbon monolayers by low- energy CH<SUB>2</SUB>Br<SUB>2</SUB><SUP>+&#183;</SUP> ions: a combined ion/surface scattering and X-ray photoelectron spectroscopic investigation

Specific covalent chemical modification at the outermost atomic layers of fluorinated self-assembled monolayers (F-SAMs) on gold is achieved by bombardment with low-energy polyatomic ions (&lt;100 eV). The projectile ion CH2Br2+&#183; (m/z 172), mass and energy selected using a hybrid ion/surface scattering mass spectrometer and scattered from the F-SAM surface, CF3(CF2)7(CH2)2-S-Au, undergoes ion/surface reactions evident from the nature of the scattered ions, CH2F+ (m/z 33), CHBrF+ (m/z 111), and CF2Br+ (m/z 129). The chemical transformation of the reactive F-SAM surface was independently monitored by in situ chemical sputtering with the projectile Xe+&#183;. Representative species sputtered from the modified surface include CF2Br+, an indicator of terminal CF3 to CF2Br conversion. X-ray photoelectron spectroscopy (XPS) was used to confirm the presence of organic bromine at the surface; Br (3P3/2) and Br (3P&#189;) peaks were present at binding energies of 182 and 190 eV, respectively. XPS analysis also revealed increased surface modification at higher collision energies in these reactive ion bombardment experiments, as exemplified by the increased hydrocarbon/fluorocarbon peak ratio in the C(1s) region and incorporation of oxygen in the surface seen in the observation of an O(1s) peak

Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease

Background Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann–Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential effects of that drug. Methods We sequenced the exons of NPC1L1 in 7364 patients with coronary heart disease and in 14,728 controls without such disease who were of European, African, or South Asian ancestry. We identified carriers of inactivating mutations (nonsense, splice-site, or frameshift mutations). In addition, we genotyped a specific inactivating mutation (p.Arg406X) in 22,590 patients with coronary heart disease and in 68,412 controls. We tested the association between the presence of an inactivating mutation and both plasma lipid levels and the risk of coronary heart disease. Results With sequencing, we identified 15 distinct NPC1L1 inactivating mutations; approximately 1 in every 650 persons was a heterozygous carrier for 1 of these mutations. Heterozygous carriers of NPC1L1 inactivating mutations had a mean LDL cholesterol level that was 12 mg per deciliter (0.31 mmol per liter) lower than that in noncarriers (P = 0.04). Carrier status was associated with a relative reduction of 53% in the risk of coronary heart disease (odds ratio for carriers, 0.47; 95% confidence interval, 0.25 to 0.87; P = 0.008). In total, only 11 of 29,954 patients with coronary heart disease had an inactivating mutation (carrier frequency, 0.04%) in contrast to 71 of 83,140 controls (carrier frequency, 0.09%). Conclusions Naturally occurring mutations that disrupt NPC1L1 function were found to be associated with reduced plasma LDL cholesterol levels and a reduced risk of coronary heart disease.National Human Genome Research Institute (U.S.) (Grant 5U54HG003067-11